Minerva Surgical

Minerva Surgical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Minerva Surgical (UTRS) as of Nov 2, 2026 is 115.95 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 104.48 % — a change of 10.98% (higher).

FCF Conversion

115.95 %

YoY

10.98%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Minerva Surgical is 2023 115.95 % . FCF Conversion Rate (FCF/EBITDA) of Minerva Surgical was 2022 104.48 % . It decreases by 10.98% higher compared to the previous year.

The Minerva Surgical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
38.46 USD
Jan 1, 2020
69.51 USD
Jan 1, 2021
106.98 USD
Jan 1, 2022
104.48 USD
Jan 1, 2023
115.95 USD
The Minerva Surgical FCF Conversion history
YEARFCF ConversionYoY
115.95 %+10.98%
104.48 %-2.34%
106.98 %+53.92%
69.51 %+80.74%
38.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Minerva Surgical Stock analysis

What does Minerva Surgical do? Minerva Surgical, Inc. generates revenue through the commercialization of minimally invasive uterine healthcare solutions designed to treat abnormal uterine bleeding without necessitating hysterectomies. The company offers a suite of products targeting structural and non-structural causes of AUB, which are utilized by OB/GYNs in hospitals, ambulatory surgical centers, and physician offices. These devices address drawbacks of alternative treatments while preserving the uterus, appealing to healthcare providers seeking effective, non-invasive options for women's health. The firm's product line includes commercially available devices for minimally invasive alternatives to hysterectomy, specifically targeting the most common causes of AUB across various uterine anatomies. OB/GYNs across multiple medical settings purchase these solutions, leveraging their ability to address treatment limitations while avoiding unnecessary surgical interventions. The company's focus on preserving the uterus through non-hysterectomy methods differentiates its offerings in the women's health technology market. Minerva Surgical's revenue model relies on sales of its medical devices to healthcare providers, particularly OB/GYNs, who integrate the products into their treatment protocols for patients with abnormal uterine bleeding. The company's solutions are positioned as alternatives to traditional hysterectomy procedures, targeting a significant unmet need in women's healthcare. This approach allows the firm to capture market share by addressing both clinical and patient preference demands for less invasive care options. Minerva Surgical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Minerva Surgical stock

FCF Conversion Rate (FCF/EBITDA) of Minerva Surgical is 115.95 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Minerva Surgical changed from 104.48 % to 115.95 %, representing a 10.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Minerva Surgical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Minerva Surgical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Minerva Surgical

All Key Metrics — Minerva Surgical